← Back
NeuroTrials.ai
Neurology Clinical Trial Database

RIN-1

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorder (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Year of Publication: 2020

Authors: Tahara M, Oeda T, Okada K, ..., Aoki M

Journal: The Lancet Neurology

Citation: Lancet Neurol 2020;19:298-306

Link: https://pubmed.ncbi.nlm.nih.gov/32199095/


Clinical Question

Is rituximab effective and safe for relapse prevention in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder?

Bottom Line

Rituximab completely prevented relapses over 72 weeks (0% vs 37% placebo, P=0.0058) in AQP4-positive NMOSD patients, providing the first randomized controlled trial evidence supporting rituximab use in this condition, which had previously relied on observational data alone.

Major Points

  • First double-blind, placebo-controlled RCT of rituximab in NMOSD
  • 38 AQP4-IgG seropositive NMOSD patients randomized 1:1 to rituximab or placebo
  • Zero relapses in rituximab group vs 7 relapses in 19 placebo patients (37%) over 72 weeks, P=0.0058
  • Study stopped early by the data safety monitoring board due to overwhelming efficacy
  • CD19+ B cells depleted to <1% within 2 weeks and maintained throughout in rituximab group
  • EDSS improved in rituximab group (mean change −0.2) vs worsened in placebo group (mean change +0.8)
  • No serious infections or unexpected safety signals in the rituximab group
  • Supports rituximab as a cost-effective alternative to newer biologics (inebilizumab, satralizumab, eculizumab) in NMOSD

Design

Study Type: Multicenter, double-blind, placebo-controlled, phase II/III randomized controlled trial

Randomization: 1

Blinding: Double-blind; identical placebo infusions; independent relapse adjudication committee blinded to treatment

Enrollment Period: 2017-2019

Follow-up Duration: 72 weeks

Centers: 7

Countries: Japan

Sample Size: 38

Analysis: Intention-to-treat; Kaplan-Meier survival analysis for time to first relapse; Fisher's exact test; log-rank test


Inclusion Criteria

  • Age 18-70 years
  • NMOSD per 2015 IPND criteria
  • Anti-AQP4 antibody seropositive
  • ≥1 relapse in preceding 2 years or ≥2 relapses in preceding 4 years
  • EDSS score 0-7.0
  • Stable or no immunosuppressive therapy for ≥30 days before screening

Exclusion Criteria

  • Previous treatment with rituximab or other anti-CD20 therapy
  • Active infection including hepatitis B or C, HIV, or tuberculosis
  • CD4+ T-cell count <250/μL
  • IgG <5.0 g/L
  • Relapse within 30 days of randomization
  • Pregnant or lactating women

Arms

FieldRituximabControl
InterventionRituximab 375 mg/m² IV weekly × 4 at baseline, then single infusion at weeks 24 and 48Matching placebo IV infusions on same schedule
Duration72 weeks72 weeks

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Time to first relapse over 72 weeksPrimary37% relapsed (7/19)0% relapsed (0/19)37%0.0058
Change in EDSS from baselineSecondary+0.8-0.2<0.05
Annualized relapse rateSecondary0.360<0.01
Change in visual acuity (logMAR)SecondaryWorsenedStableNS
CD19+ B-cell count depletionSecondaryNo change<1% by week 2, maintained<0.001
Infusion reactionsAdverse5%26%NS
Upper respiratory infectionAdverse16%21%NS
Urinary tract infectionAdverse11%5%NS

Subgroup Analysis

Benefit consistent regardless of baseline EDSS, disease duration, or concomitant immunosuppressive therapy use


Criticisms

  • Very small sample size (N=38) limits generalizability and detection of rare adverse events
  • Conducted exclusively in Japan — ethnic/genetic homogeneity may not represent global NMOSD populations
  • Short follow-up (72 weeks) does not assess long-term efficacy, hypogammaglobulinemia risk, or sustained remission after discontinuation
  • Study stopped early, which can overestimate treatment effects
  • No active comparator — standard of care (azathioprine, mycophenolate) not tested
  • Concomitant low-dose corticosteroids allowed in both groups, potentially confounding results

Funding

Japan Agency for Medical Research and Development (AMED)

Based on: RIN-1 (The Lancet Neurology, 2020)

Authors: Tahara M, Oeda T, Okada K, ..., Aoki M

Citation: Lancet Neurol 2020;19:298-306

Content summarized and formatted by NeuroTrials.ai.